We examined the prospective associations between breast milk concentrations of erythropoietin, a factor with trophic effects on infant gut epithelia, and the risk of mother-tochild transmission (MTCT) of human immunodeficiency virus (HIV) through breast-feeding in a study of 59 MTCT cases and 116 controls nested within a cohort of antiretroviral-naive HIV-infected Tanzanian women. Controls were matched to cases on the basis of the time from birth when the breast milk sample was collected. The risk of MTCT was inversely related to breast milk erythropoietin concentration (adjusted odds ratio for highest vs lowest erythropoietin concentration tertile, 0.34 [95% confidence interval, 0.14-0.82];
In the absence of interventions, transmission of human immunodeficiency virus (HIV) occurs through breast-feeding in about 5%-20% of children born to HIV-positive women, which accounts for an estimated one-third to one-half of all HIV infections in African children [1] . Although avoidance of breast-feeding would eliminate this risk, replacement feeding during the first 6 months is not recommended in developing countries, where cost is prohibitive and the lack of sanitary conditions for preparation of replacement foods introduces risks for other infections. Not all infants who are breast-fed by HIV-infected mothers become infected; thus, identifying potential factors in breast milk that are protective against motherto-child transmission (MTCT) is an important area of research to prevent MTCT in resource-poor settings.
It has been hypothesized that erythropoietin in human milk may be protective against MTCT [2] . Erythropoietin is a protein secreted by the kidneys that stimulates red blood cell production and that is found in breast milk [3] . The cytoprotective properties of erythropoietin [4] might promote the integrity of the mammary epithelium, which is necessary to prevent leakage of HIV particles from blood into milk. Mammary gland leakiness associated with subclinical breast inflammation is a risk factor for MTCT [5, 6] . In addition, erythropoietin may promote gut integrity in infants, because premature infants given recombinant human erythropoietin had a lower incidence of necrotizing enterocolitis [7] .
Using a nested case-control study design, we prospectively examined the association between breast milk erythropoietin concentrations and the risk of MTCT among infants born to HIV-infected women in Tanzania.
Methods. We conducted a case-control study nested in a cohort of 1078 HIV type 1 (HIV-1)-infected Tanzanian women who participated in a randomized, double-blind, placebo-controlled trial of vitamins. Women were recruited during pregnancy and followed up with their infants throughout the lactation period [8] . Baseline information was obtained on sociodemographic characteristics, clinical and immunological HIV disease stage, and potential risk factors for transmission of HIV. Vertical transmission of HIV was determined by tests of blood samples collected from the children at birth, at 6 weeks of age, and every 3 months thereafter. Samples were tested by use of enzyme-linked immunosorbent assay and/or Western blot analysis or by use of polymerase chain reaction for samples from children younger than 18 months (Amplicor HIV-1 DNA assay; version 1.5; Roche Diagnostics). Children who tested negative for HIV at birth and at 6 weeks of age but tested positive for HIV anytime thereafter were presumed to have been infected via breast-feeding. Approximately every 3 months, ∼10 mL of breast milk was collected from each woman by manual expression from either breast and stored at Ϫ70ЊC.
Cases of MTCT were defined as women who transmitted HIV-1 to their infants through breast milk ( ). We aimed n p 61 to select samples of breast milk that had been collected before the child's first HIV-positive test result or at the same time as the first HIV-positive test result if an earlier sample was not available. There was no suitable sample in 2 cases, and so the final study population comprised 59 cases of MTCT. In 27 cases, a sample was available from 4-24 weeks before the first positive test result. In the remaining 32 cases, the only available breast milk sample was from either 124 weeks before the child's first positive test result ( ), at the same time as the child's n p 22 first positive test result ( ), or within the 4 weeks prior to n p 8 the child's first positive test result ( ). We selected 2 conn p 2 trols per case from the pool of mothers whose child's final HIV status was negative after the end of breast-feeding. Controls were individually matched to cases on the basis of the time ‫1ע(‬ week) since delivery of the collection of the breast milk sample. Control samples were only available within 2 weeks for 3 cases and within 3-4 weeks for 5 cases. Two of the control samples had insufficient volume for erythropoietin analyses, and suitable replacements could not be found; thus, there were 2 case-control sets with only 1 control per case, and the total number of controls was 116.
This study was approved by the Institutional Review Board of the Harvard School of Public Health and the Research and Publications Committee of Muhimbili University of Health and Allied Sciences.
Erythropoietin was quantified in whole milk samples by means of enzyme-linked immunosorbent assay (Human Erythropoietin Quantikine IVD kit; R&D Systems). One aliquot of milk was centrifuged and separated into aqueous and cell fractions prior to freezing. HIV-1 viral RNA was isolated from the cell-free aqueous milk fraction by use of a High Pure viral RNA kit (Roche Diagnostics). The cell-free viral load was quantified by use of the ultrasensitive protocol of the Amplicor HIV-1 Monitor test (version 1.5; Roche Diagnostics), as detailed elsewhere [9] .
We compared baseline characteristics of case individuals and control individuals by use of the Wilcoxon matched-pairs rank sum test for continuous variables and the McNemar test for categorical variables. The association between breast milk erythropoietin concentration and transmission of HIV was examined by fitting conditional logistic regression models with case-control status as the outcome and ordinal categories that represented tertiles of erythropoietin concentration as the exposure. Adjusted odds ratios and 95% confidence intervals were estimated from a model that included risk factors for MTCT such as maternal CD4 + cell counts, clinical stage of HIV disease at baseline, and assignment to the vitamin A supplementation arm of the trial [8, 10] . To test for dose-response associations between the concentration of erythropoietin in breast milk and MTCT, we introduced an ordinal variable that represented the tertiles as a continuous variable into the regression models and tested its statistical significance with the use of the Wald test. To examine whether relationships between erythropoietin concentrations and MTCT could be mediated by changes in breast milk viral load, we evaluated cross-sectional associations between erythropoietin and cell-free virus concentrations in milk, using cases and controls as a single sample. High cell-free virus concentrations in breast milk were defined dichotomously, with the median value among the case samples being used as the cutoff point [9] . The proportions of women with high cell-free viral loads were compared across erythropoietin concentration tertiles with use of the Cochran-Armitage test for trends.
Results. Maternal age, body mass index, and hemoglobin concentration did not differ between case mothers and control mothers ( Table 1) . As expected, case mothers had lower CD4 + cell counts, more advanced disease stages, and higher cell-free viral loads in milk than control mothers.
The median erythropoietin concentrations were 0.8 mIU/ mL in case samples and 4.1 mIU/mL in control samples (P p ). Forty-seven percent of case samples and 35% of control .03 samples had erythropoietin concentrations below the detection limit of 0.6 mIU/mL. The risk of MTCT was inversely related to erythropoietin concentration (Table 2) . After adjustment for potential confounders, women with erythropoietin concentrations in the highest tertile had a 66% reduced risk of transmitting HIV to their children compared with those in the lowest tertile ( for trend). After additional adjustment for P p .02 breast milk viral load, the odds ratio for MTCT between the highest and lowest tertiles of erythropoietin concentration was attenuated to 0.45 (95% confidence interval, 0.17-1.22), which suggests that viral load might be in the causal pathway between erythropoietin concentration and MTCT. Nevertheless, the attenuation was mild and the proportion of women with high cell-free viral load was not significantly different across tertiles of erythropoietin concentration (data not shown).
Discussion. In this nested case-control study, the transmission of HIV through breast-feeding was inversely related to the concentration of erythropoietin in breast milk. Although we are unable to attribute causality to the findings given the observational nature of the study, the results suggest a protective effect of erythropoietin against MTCT.
It has been hypothesized that erythropoietin in breast milk may prevent MTCT due to its potential effects on the integrity of mammary or infant intestinal epithelia [2] . In newborn rats, administration of recombinant human erythropoietin increased small bowel length and villus surface area [11] , inhibited apoptosis, and stimulated intestinal cell proliferation [12] . Supplementation of premature infants with recombinant human erythropoietin decreased the incidence of necrotizing enterocolitis [7] . The endocytes that line the mammary gland are morphologically similar to intestinal enterocytes and may similarly be affected by erythropoietin. Human mammary epithelial cells express erythropoietin and its receptor [3] , which indicates mammary production of erythropoietin and suggests that erythropoietin may have specific functions within the breast. An intact mammary mucosa may be less permeable to free or cell-associated virus. Because we did not find associations between erythropoietin concentration and viral load in breast milk, a potential effect of erythropoietin on the infant intestinal mucosa may be more likely.
Some researchers have suggested that HIV-infected patients have a blunted erythropoietin response to anemia [13] . The normal response to anemia is increased production of erythropoietin by the kidneys and increased serum erythropoietin concentrations. HIV-infected patients who had stage III disease (as classified by the Centers for Disease Control and Prevention) had a significantly more impaired erythropoietin response to anemia than did patients with stage I or stage II disease [13] . Another study found no difference in serum erythropoietin concentrations between individuals with different HIV disease stages [14] . It is unclear whether erythropoietin concentration in breast milk is affected by HIV status or disease stage. However, we controlled for indicators of HIV disease stage in the analysis to minimize potential confounding by this factor.
The erythropoietin concentrations in breast milk samples from the control individuals in our study (median, 4.1 mIU/ mL) are in agreement with those reported in a previous study by Juul et al [3] (median, 4.7 mIU/mL). In their study, erythropoietin concentrations were found to increase during lactation. Because we matched cases to controls by the time since delivery when the sample was collected, fluctuations in erythropoietin concentrations during lactation are not a likely source of bias in our study. One potential limitation of our study is the fact that for some of the samples the time between the assessment of the exposure and the outcome was relatively long (124 weeks). The interpretability of the results could have been affected if erythropoietin concentrations were different in samples collected closer to the estimated time of transmission; nevertheless, results were not substantially different in supplemental analyses limited to cases with the exposure assessed at р24 weeks from the first positive HIV test result.
The results from our case-control study suggest a possible protective effect of breast milk erythropoietin against MTCT. The gut-trophic and anti-inflammatory properties of erythropoietin may contribute to the prevention of MTCT. Breast milk erythropoietin concentrations can be increased with administration of recombinant human erythropoietin [15] . Further research should be considered to elucidate the potential mechanisms and to examine whether breast milk erythropoietin concentrations can be influenced by dietary or other modifiable factors.
